Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Dorr, Patrick; Westby, Mike; Dobbs, Susan; Griffin, Paul; Irvine, Becky; Macartney, Malcolm; Mori, Julie; Rickett, Graham; Smith‐Burchnell, Caroline; Napier, Carolyn; Webster, Rob; Armour, Duncan; A. Price, David; Stammen, Blanda; Wood, Anthony; Perros, Manos

doi:10.1128/aac.49.11.4721-4732.2005

Public

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Published in Antimicrobial Agents and Chemotherapy • Oct 26, 2005

Authors:

Patrick Dorr

Mike Westby

Susan Dobbs

Abstract

Maraviroc (UK-427,857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. Maraviroc is the product of a medicinal chemistry effort initiated following identification of an imidazopyridine CCR5 ligand from a h...

View

Paywalled

Subject

Maraviroc

CCR5 receptor antagonist

Entry inhibitor

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions